000150967 001__ 150967
000150967 005__ 20251017144609.0
000150967 0247_ $$2doi$$a10.3390/vaccines9111321
000150967 0248_ $$2sideral$$a125373
000150967 037__ $$aART-2021-125373
000150967 041__ $$aeng
000150967 100__ $$0(orcid)0000-0003-4242-5464$$aIguacel, Isabel$$uUniversidad de Zaragoza
000150967 245__ $$aAssociation between COVID-19 Vaccine Side Effects and Body Mass Index in Spain
000150967 260__ $$c2021
000150967 5060_ $$aAccess copy available to the general public$$fUnrestricted
000150967 5203_ $$aCOVID-19 vaccines have shown high efficacy, with most side effects being mild-moderate and more frequently reported by females and people at younger ages. Since no studies have assessed the impact that weight status could have on the reported adverse reactions, we aim to study the association between weight status and reported side effects. We included data on 2136 adults from an online survey conducted from 6 May to 9 June 2021. The questionnaire was filled in by participants over Google forms. Generalized Linear Mixed Models were used. A higher risk of presenting fever \u226538\u00b0, vomiting, diarrhea and chills was found in those with a non-overweight status compared to those overweight after adjusting for age, sex, education, medication to preventrelieve post-vaccination effects and vaccine administered. When adjusting, most of the significant effects, in the association between side effects of the COVID-19 vaccine and weight status, did not remain significant. In conclusion, a non-overweight status was associated with a higher risk of presenting fever \u226538\u00b0, vomiting, diarrhea and chills compared to those overweight. Nevertheless, most of the reported side effects to COVID-19 vaccine were not associated with a higher risk of presenting more adverse effects, and individual differences were determined by sex and age.
000150967 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttps://creativecommons.org/licenses/by/4.0/deed.es
000150967 590__ $$a4.961$$b2021
000150967 591__ $$aMEDICINE, RESEARCH & EXPERIMENTAL$$b59 / 139 = 0.424$$c2021$$dQ2$$eT2
000150967 591__ $$aIMMUNOLOGY$$b77 / 162 = 0.475$$c2021$$dQ2$$eT2
000150967 592__ $$a1.004$$b2021
000150967 593__ $$aDrug Discovery$$c2021$$dQ1
000150967 593__ $$aPharmacology$$c2021$$dQ1
000150967 593__ $$aInfectious Diseases$$c2021$$dQ1
000150967 593__ $$aImmunology$$c2021$$dQ1
000150967 594__ $$a4.5$$b2021
000150967 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000150967 700__ $$aLuna Maldonado, Aurelio
000150967 700__ $$aLuna Ruiz-Cabello, Aurelio
000150967 700__ $$aCasaus, Marta
000150967 700__ $$0(orcid)0000-0003-0454-653X$$aMoreno, Luis Alberto$$uUniversidad de Zaragoza
000150967 700__ $$0(orcid)0000-0001-6469-9189$$aMartínez-Jarreta, Begoña$$uUniversidad de Zaragoza
000150967 7102_ $$11006$$2255$$aUniversidad de Zaragoza$$bDpto. Fisiatría y Enfermería$$cÁrea Enfermería
000150967 7102_ $$11012$$2613$$aUniversidad de Zaragoza$$bDpto. Farmac.Fisiol.y Med.L.F.$$cÁrea Medicina Legal y Forense
000150967 773__ $$g9, 11 (2021), 1321 [12 pp.]$$tVaccines$$x2076-393X
000150967 8564_ $$s281061$$uhttps://zaguan.unizar.es/record/150967/files/texto_completo.pdf$$yVersión publicada
000150967 8564_ $$s2667209$$uhttps://zaguan.unizar.es/record/150967/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000150967 909CO $$ooai:zaguan.unizar.es:150967$$particulos$$pdriver
000150967 951__ $$a2025-10-17-14:16:23
000150967 980__ $$aARTICLE